---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-005889"
form_type: "8-K"
ticker: null
cik: "0001840904"
company_name: "ATAI Life Sciences N.V."
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T08:28:37.501738+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Anne Johnson named CFO of atai Life Sciences; Stephen Bardin departs

## Summary
- Stephen Bardin steps down as CFO effective Feb 6, 2024; will advise through March 31, 2024.
- Anne Johnson, previously Interim CFO and Chief Accounting Officer, appointed CFO.
- Bardin receives severance: 9 months base salary, COBRA, $149,600 bonus, $30,462 parental leave.
- Johnson brings ~20 years biopharma experience from Aruvant, Chimerix, PPD, and Xanodyne.
- Separation agreement includes release of claims and non-disclosure covenants.

## SEC filing metadata
- accession: 0001140361-24-005889
- form_type: 8-K
- cik: 0001840904
- company_name: ATAI Life Sciences N.V.
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840904/000114036124005889/0001140361-24-005889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840904/000114036124005889/ef20020799_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-005889
- JSON: https://secwatch.observer/filing/0001140361-24-005889.json
- Plain text: https://secwatch.observer/filing/0001140361-24-005889.txt

## Key facts
- Executive change
  Anne Johnson was appointed as Chief Financial Officer at ATAI Life Sciences N.V..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective February 6, 2024, Ms. Johnson was appointed the Company’s Chief Financial Officer, succeeding Mr. Bardin.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840904/000114036124005889/0001140361-24-005889-index.htm
- Executive change
  Stephen Bardin departed as Chief Financial Officer at ATAI Life Sciences N.V..
  - Action: departed
  - Role: Chief Financial Officer
  source text: on February 1, 2024, the Company and Mr. Bardin reached an agreement regarding Mr. Bardin’s departure from his position as the Company’s Chief Financial Officer (the “ Separation Agreement ”), effective as of February 6, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840904/000114036124005889/0001140361-24-005889-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.